Carcinoma, Non-Small-Cell Lung Clinical Trials in Lexington, Kentucky

7 studies are recruiting for carcinoma, non-small-cell lung in Lexington, Kentucky right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

   The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of non-viral lipid nano…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Markey Cancer Center, Lexington, Kentucky

   Locations

   10 in total

   Run by

   Genprex, Inc.

   See if you can join NCT04486833 on ClinicalTrials.gov

2. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

   The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   CHI Saint Joseph Cancer Center - East, Lexington, Kentucky

   Locations

   418 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06119581 on ClinicalTrials.gov

3. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

   The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective th…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Baptist Health Lexington, Lexington, Kentucky

   Locations

   369 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06890598 on ClinicalTrials.gov

4. KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

   The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or non-squamous NSCLC…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Kentucky Markey Cancer Center ( Site 0019), Lexington, Kentucky

   Locations

   46 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT04165070 on ClinicalTrials.gov

5. KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

   This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and additional substudies. Each substu…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Kentucky Markey Cancer Center ( Site 0019), Lexington, Kentucky

   Locations

   47 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT04165798 on ClinicalTrials.gov

6. A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

   Researchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the i…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Kentucky Chandler Medical Center ( Site 0019), Lexington, Kentucky

   Locations

   34 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06780085 on ClinicalTrials.gov

7. A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

   The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Lexington, Kentucky

   Locations

   304 in total

   Run by

   AstraZeneca

   See if you can join NCT06868277 on ClinicalTrials.gov